Skip to main content
Premium Trial:

Request an Annual Quote

BioGenex Takes Over Support for Xmatrx Platform Following End of Abbott Partnership

NEW YORK (GenomeWeb News) – BioGenex and Abbott Molecular today announced that BioGenex will take over direct sales and support responsibility for the co-branded Xmatrx instruments, auto FISH reagents, and consumables.

The two firms had a "long and successful collaboration and partnership," said BioGenex, centered on BioGenex's Xmatrx platform, and in 2009 extended an assay deal to market the Xmatrx platform for the automation of Abbott's FISH product line.

Xmatrx FISH, BioGenex said, allows for the walk-away automation of all assay steps necessary to perform Abbott's FISH test, from baking to final cover slip. BioGenex will now support current Xmatrx customers.

Based on individual customer requests, the Fremont, Calif.-based company will also enable the platform to perform other slide-based assays, such as immunohistochemistry, in situ hybridization, and microRNA assays. BioGenex's Xmatrx Elite system comprises a platform for full automation of any slide-based assay, the firm said.

"Abbott and BioGenex are working closely and are committed to ensure seamless transition," BioGenex CEO Krishan Kalra said in a statement. "Hospitals, labs, and research institutions that use Xmatrx can be assured that they will get best in class service and support."

Filed under

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.